00:50:05 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-16 X-dag ordinarie utdelning BRAINP 0.00 DKK
2024-05-15 Årsstämma 2024
2024-05-07 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 X-dag ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 X-dag ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa. Brain+ har sitt huvudkontor i Köpenhamn.
2024-05-24 09:33:00
Copenhagen, Denmark, 24 May 2024 - Brain+ A/S (Nasdaq First North: BRAINP) 

Brain+ A/S ("Brain+" or "the company") is inviting its shareholders, other investors and stakeholders to an online investor meeting, which will take place on Monday, 27 May 2024 at 16:30 CEST via the Stokk.io event platform (Events on Stokk.io - Stokk.io (https://www.stokk.io/events-and-presentations/)).

At the investor meeting, CEO and founder Kim Baden-Kristensen will give an update on Brain+' business activities and plans with emphasis on the status and potential of the UK-focused go-to-market and commercial scaling strategy for the CST-Assistant. The CST-Assistant is the most advanced of Brain+' proprietary health tech solution for better dementia management. CFO Hanne Vissing Leth will provide details on the earlier announced upcoming public offering of Units (new shares and warrants), which is 60% secured via signed pre-subscriptions and guarantor commitments from management, board and investors.

Newly elected Chairman Tim Juergens, who is an experienced health tech executive and investor, will share his insights on the potential of health tech solutions in dementia management and specifically his view on Brain+' position and value propositions. Tim Juergens has been board observer and advisor to management since February 2024.

The investor meeting follows Brain+' Annual General Meeting (AGM), which was held on Wednesday, 22 May 2024. At the AGM, both the partially secured Unit Offering to provide funding to execute the UK focused commercialization plan and the election of Tim Juergens as new board member and Chairman was adopted with all votes represented.

Participation in the Investor Event

The Brain+ investor meeting will take place on Monday 27 May 2024 at 16:30 CEST as an online event via the Stokk.io platform. The meeting can be accessed directly via the following link:  Brain+ investor-update-w-new-chairman/ (https://eur05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fapp.stokk.io%2Fapp%2Fbrain%2Fevent%2F152%2Finvestor-update-w-new-chairman%2F&data=05%7C02%7Channe%40brain-plus.com%7C8b24e83467a6407e250c08dc7b2a6ee6%7Cf2f9babfec61480d81d3c163d28ca06a%7C0%7C0%7C638520669408978149%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=ySNDITm8fwcqDM3UsnTrqF4E%2F827vQLWdEY016Y%2BQjY%3D&reserved=0)

It is possible for investors and other participants to upload questions on the platform prior to the meeting. Questions can also be asked online in writing during the meeting.

For those unable to participate in the meeting, a replay of the webcast will be available on the Stokk.io platform after the event.

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31393317 (SMS), kim@brain-plus.com

Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing several million people affected by dementia by 2030.